• 제목/요약/키워드: lung toxicity

검색결과 423건 처리시간 0.024초

Bleomycin 유도 폐독성에 동반된 자연성 종격동 기종 (Spontaneous Pneumomediastinum Accompanied by Bleomycin-Induced lung Toxicity)

  • 도영우;조석기;이영옥;이응배
    • Journal of Chest Surgery
    • /
    • 제41권6호
    • /
    • pp.791-794
    • /
    • 2008
  • Bleomycin에 의한 폐독성은 잘 알려져 있으나, Bleomycin 유도 폐독성 후에 기흉 없이 발생한 자연성 종격동 기종은 드문 것으로 알려져 있다. 따라서, Bleomycin 항암 치료를 받은 환자에서 호흡 곤란의 악화 원인으로 자연성 종격동 기종도 고려해야 할 필요가 있다. 저자들은 생식 세포종으로 Bleomycin 항암치료를 받은 후 심한 호흡곤란을 호소하는 두 명의 환자에서 기흉이 없는 자연성 종격동 기종을 진단하고 치료 하였기에 보고하는 바이다.

Thoracic Re-irradiation for Locally Recurrent Lung Cancer

  • Aktan, Meryem;Kanyilmaz, Gul;Koc, Mehmet;Aras, Serhat
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권11호
    • /
    • pp.5041-5045
    • /
    • 2016
  • Background: Patients with recurrent or progressive lung cancer experience a significant symptom burden, negatively affecting quality of life and reducing life expectancy. Thoracic re-irradiation can be used for palliative treatment to relieve symptoms or as a curative treatment. Methods: Using patient charts, we identified and reviewed 28 cases that had received palliative thoracic re-irradiation for recurrent lung cancer. Results: Before re-irradiation, 32% of patients had stage III non-small cell lung cancer and six had small cell lung cancer. The median interval between treatments was 18.7 months. Median follow-up was 31.2 months from the initial radiotherapy and 5 months after re-irradiation. A better performance status before re-irradiation (<80 vs >80, p=0.09) and a lower overlap 90% isodose (<70 vs >70, p=0.09) showed trends toward improved survival. Grade 1-2 toxicity from re-irradiation was recorded in 12/28 patients, and no grade 3 or 4 acute toxicity was encountered. Conclusion: The role of palliative treatment in survival is not clear but it can provide symptomatic relief in patients, with no high grade toxicity. Further studies with greater patient numbers and longer follow-up times should facilitate determination of the role of this treatment in toxicity and effects on survival.

한국산 백석면이 랫드의 폐 기능에 미치는 영향 평가 연구 (Effect of Korean Chrysotile on the Lung Function of Rats)

  • 정용현;강민구;한정희
    • 한국산업보건학회지
    • /
    • 제24권2호
    • /
    • pp.130-136
    • /
    • 2014
  • Objectives: To evaluate the pulmonary toxicity of Korean Chrysotile(KC), the lung function and the number of fibers in the bronchoalveolar lavage fluid of Sprague-Dawley rats instilled with KC were estimated. Materials: Rats were administered 1 mg KC by a single intratracheal instillation. At each time point(5 days, 5 weeks, 10 weeks), the lung function of the rats was analyzed by pressure transducer and the amount of asbestos in the bronchoalveolar lavage fluid of the rats was calculated by transmission electron microscope equipped with energy dispersive X-ray spectrometer. Results: The lung function of the rats at 5 days after instillation of KC was confirmed to be degraded. However, after 5 weeks the test groups showed a tendency to recover lung function. Still, after 10 weeks the lung function of the test groups had not recovered completely. The number of fibers in the bronchoalveolar lavage fluid of the rats instilled with KC rapidly decreased. At 5 weeks the number of fibers had reduced to approximately 1/2 of that found at 5 days. Over time, at 10 weeks it had rapidly decreased to 1/100 that found at 5 days. Conclusions: Korean chrysotile fibers rapidly decreased in the lungs of rats, but the lung function of rats instilled KC does had not completely recovered by 10 weeks.

HMC05의 배양 Chinese Hamster Lung 세포를 이용한 염색체이상 시험 (A Chromosome Aberration Test of HMC05 on Cultured Chinese Hamster Lung Cells)

  • 신흥묵
    • 대한본초학회지
    • /
    • 제25권1호
    • /
    • pp.1-7
    • /
    • 2010
  • Objectives : We investigated genetic toxicity of HMCO5 in relation to chromosome aberration test on Cultured Chinese Hamster Lung (CHL) in the presence and absence of S-9 mix. Methods : Experimental groups were divided into two groups: with S-9mix (+S) or without S-9 mix (-S). -S group was also divided 2 series by treatment hours (6 hr: 6-S; or 24 hr; 24-S). Each group treated with vehicle only (complete culture medium), HMCO5 (1,250, 2,500, $5,000\;{\mu}g/ml$), and cyclophosphamide monohydrate (CPA) and ethylmethanesulfonate (EMS), respectively. Results : HMC05 did not show any aberrant metaphase. However, there were significant (p < 0.01) aberrant metaphases with CPA in S+ and with EMS in S-. Conclusions : These results indicate that HMC05 formula does not show any toxicity in chromosome aberration test.

Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer

  • Li, Li;Huang, Xin-En
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권5호
    • /
    • pp.2583-2585
    • /
    • 2016
  • Objectives: To evaluate efficacy and toxicity in patients with advanced lung cancer, including non-small cell and small cell variants (NSCLC and SCLC), treated with thalidomide plus chemotherapy. Methods: Fourteen patients with advanced lung cancer were scheduled to receive chemotherapy combined with thalidomide. All patients in this study received thalidomide (100 mg orally per night before sleeping, produced by Changzhou Pharmaceutical Factory Co.Ltd) after the start of chemotherapy for at least 14 days. Chemotherapy was administered according to the condition of patients. After at least 14 days of treatment, efficacy and toxicity were evaluated. Results: There were 6 female and 8 male patients with advanced lung cancer recruited into this study, including 2 with SCLC and 12 with NSCLC. The median age was 56.7 (44-65) years. Progressive disease was observed in 12 patients (12/14), and stable disease in 2 (2/14). Grade 1 to 2 myelosuppression was observed in 4/14 patients, and Grade 1 to 2 elevation of hepatic enzymes was recorded in 5/14 patients. Adverse effects on the gastrointestinal tract were documented in 2/14 patients, all beingGrade 1. No Grade 3-4 toxicity was recorded. No treatment related deaths occurred. Conclusions: Our results demonstrate that thalidomide combined with chemotherapy is mildly effective and safe for treating patients with advanced lung cancer. However, further evaluation of this combination is warranted.

A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer

  • Yang, Song
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권14호
    • /
    • pp.5963-5966
    • /
    • 2015
  • Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabine and nedaplatin in treating patients with non-small cell lung cancer. Methods: Clinical studies evaluating the efficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety for patients with non-small cell lung cancer were identified using a predefined search strategy. Pooled response rates for gemcitabine and nedaplatin were calculated. Results: In gemcitabine and nedaplatin based regimens, 4 clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. The pooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4 neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting, diarrhea, and hepatic dysfunction. There were no treatment-related deaths. Conclusion: This evidence based analysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate and accepted toxicity for treating patients with non-small cell lung cancer.

Twenty-Eight-Day Repeated Inhalation Toxicity Study of Nano-Sized Neodymium Oxide in Male Sprague-Dawley Rats

  • Kim, Yong-Soon;Lim, Cheol-Hong;Shin, Seo-Ho;Kim, Jong-Choon
    • Toxicological Research
    • /
    • 제33권3호
    • /
    • pp.239-253
    • /
    • 2017
  • Neodymium is a future-oriented material due to its unique properties, and its use is increasing in various industrial fields worldwide. However, the toxicity caused by repeated exposure to this metal has not been studied in detail thus far. The present study was carried out to investigate the potential inhalation toxicity of nano-sized neodymium oxide ($Nd_2O_3$) following a 28-day repeated inhalation exposure in male Sprague-Dawley rats. Male rats were exposed to nano-sized $Nd_2O_3-containing$ aerosols via a nose-only inhalation system at doses of $0mg/m^3$, $0.5mg/m^3$, $2.5mg/m^3$, and $10mg/m^3$ for 6 hr/day, 5 days/week over a 28-day period, followed by a 28-day recovery period. During the experimental period, clinical signs, body weight, hematologic parameters, serum biochemical parameters, necropsy findings, organ weight, and histopathological findings were examined; neodymium distribution in the major organs and blood, bronchoalveolar lavage fluid (BALF), and oxidative stress in lung tissues were analyzed. Most of the neodymium was found to be deposited in lung tissues, showing a dose-dependent relationship. Infiltration of inflammatory cells and pulmonary alveolar proteinosis (PAP) were the main observations of lung histopathology. Infiltration of inflammatory cells was observed in the $2.5mg/m^3$ and higher dose treatment groups. PAP was observed in all treatment groups accompanied by an increase in lung weight, but was observed to a lesser extent in the $0.5mg/m^3$ treatment group. In BALF analysis, total cell counts, including macrophages and neutrophils, lactate dehydrogenase, albumin, interleukin-6, and tumor necrosis factor-alpha, increased significantly in all treatment groups. After a 4-week recovery period, these changes were generally reversed in the $0.5mg/m^3$ group, but were exacerbated in the $10mg/m^3$ group. The lowest-observed-adverse-effect concentration of nano-sized $Nd_2O_3$ was determined to be $0.5mg/m^3$, and the target organ was determined to be the lung, under the present experimental conditions in male rats.

H-약침(藥鍼)의 급성(急性).아급성(亞急性) 독성실험(毒性實驗) 및 항암효과(抗癌效果)에 관(關)한 실험적(實驗的) 연구(硏究) (The Study on Acute.Subacute Toxicity and Anti-cancer Effect of H Herbal-acupuncture)

  • 김태희;권기록;이선구
    • 대한약침학회지
    • /
    • 제5권2호
    • /
    • pp.120-136
    • /
    • 2002
  • Objectives : The purpose of this study is to investigate Acute and Subacute Toxicity, and Anti-cancer Effect of H Herbal-acupuncture on mice and rats. Methods : Balb/c mice were injected intraperitoneally with H Herbal-acupuncture for $LD_{50}$ and acute toxicity test. Sprague-Dawley rats were experimented in the same way for subacute toxicity test. H Herbal-acupuncture was injected into abdomen of mice having S-180 cancer cell line. Result : 1. During the test, $LD_{50}$ could not be counted since there was no expired subjects. 2. In an acute toxicity test, the loss of motility and reflex action was observed, but weight increased in the treatment group, compared with those in the normal group (P<0.05). 3. In an acute toxicity test of serum biochemical values of mice, glucose increased in the treatment group II while total cholesterol was increased in the all treatment groups (P<0.05). 4. In a subacute toxicity test, a little loss of motility and reflex action was observed in the treatment group. Weight of mice in the treatment group decreased on the 28th day. 5. In a subacute toxicity test, liver weight was decreased but lung weight of mice increased in the all treatment groups (P<0.05). 6. As a result of measuring Complete Blood Count test (CBC) of rat, HCT was decreased in treatments even though it was not significant, compared with the normal group (P<0.05). 7. In a serum biochemical value test of subacute toxicity, total protein and albumin decreased in the all treatment groups. Creatinine, glucose, GOT increased in the treatment group I compared with the control group. Alkaline phos-phatase decreased in treatment II group, compared with the control group (P<0.05). 8. Median survival time that was measured in the rats treated with sarcoma-180 cancer cell Median decreased in the treatment group, compared with the control group (P<0.05). 9. Natural killer cell activity showed significant reduction at 100:1 and 10:1 E/T ratio while it increased at 50:1 E/T ratio. It is inferred that there was an error in the experiment (P<0.05). 10. In an interleukin-2 productivity test, even though it decreased in lung cancer, and increased in abdomen cancer, but it was only a small difference (P<0.005). 11. After injecting B16F10 cell into a capillary vessel of C57BL/6 mice and generating metastasized lung cancer, the lung was examined with the naked eye. It was not possible to see metastasized cancer in the all groups on the seventh day but the cancer was viewed on the fourteenth day. The number and volume of metastasized cancer in the treatment group enlarged in the treatment group, compared with the control group. Conclusion : According to the results, H herbal-acupuncture took no effects in cancer.

Cyclohexane에 의한 흰쥐의 폐독성 (Effect of Cyclohexnae on the Lung Toxicity in Rats)

  • 전태원;이상일;윤종국
    • 대한의생명과학회지
    • /
    • 제6권4호
    • /
    • pp.245-251
    • /
    • 2000
  • Cyclohexane에 의한 생체장기의 독성을 검토할 목적으로 흰쥐에 체중 kg당 1.56 g의 cyclohexane을 복강으로 1일 1회 2일 간격으로 4회 투여한 다음 24시간 후에 처치하여 각 장기 (간, 신장, 비장, 심장, 소장, 위 및 폐)의 체중 당 장기무게 (%)와 조직세포중 glucose-6-phosphatase (G6Pase) 활성변동을 측정한 결과, 실험군의 체중 당 폐무게가 대조군에 비하여 현저하게 증가 (p<0.001)하였고 이와는 반대로 G6Pase 활성은 유의한 (p<0.001) 감소를 나타내었다. 그러나 폐를 제외한 장기에서는 별다른 차이를 볼 수 없었다. 이러한 결과는 cyclohexane이 주로 폐조직에 독작용을 야기시킨다는 것을 시사해 주고 있으며, 폐조직에서 malondialdehyde 함량이 대조군에 비하여 유의하게 (p<0.05) 증가된 것이 이를 뒷받침 해 주고 있다. 한편, cytochrome P450에 의해 나타나는 aniline hydroxylase 활성은 폐조직이 간조직에 비하여 대단히 낮았으며, alcohol dehydrogenase (ADH) 활성 역시 간조직 보다 현저하게 낮게 나타났다. 그리고 cyclohexane 투여로 인하여 ADH 활성은 간 및 폐조직 모두에서 증가하였으나 간조직에서 더욱 민감한 반응을 나타내었다. 이상 실험결과를 종합해 볼 때, cyclohexane은 폐조직에 주로 독성을 나타내며 이는 간조직에서 대사된 cyclohexane의 독성 중간대사산물인 cyclohexanone이 혈류를 통해 폐조직에 분포되어 나타난 결과로 사료된다.

  • PDF

Clinical Outcome of Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: The Kyung Hee University Medical Center Experience

  • Kong, Moonkyoo;Hong, Seong Eon
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권4호
    • /
    • pp.1545-1549
    • /
    • 2014
  • Background: Published studies on clinical outcome of helical tomotherapy for lung cancer are limited. The purpose of this study was to evaluate clinical outcomes and treatment-related toxicity in inoperable non-small cell lung cancer (NSCLC) patients treated with helical tomotherapy in Korea. Materials and Methods: Twenty-seven patients with NSCLC were included in this retrospective study. Radiotherapy was performed using helical tomotherapy with a daily dose of 2.1-3 Gy delivered at 5 fractions per week resulting in a total dose of 62.5-69.3 Gy. We assessed radiation-related lung and esophageal toxicity, and analyzed overall survival, locoregional recurrence-free survival, distant metastasis-free survival, and prognostic factors for overall survival. Results: The median follow-up period was 28.9 months (range, 10.1-69.4). The median overall survival time was 28.9 months, and 1-, 2-, and 3-year overall survival rates were 96.2%, 92.0%, and 60.0%. The median locoregional recurrence-free survival time was 24.3 months, and 1-, 2-, and 3-year locoregional recurrence-free survival rates were 85.2%, 64.5%, and 50.3%. The median distant metastasis-free survival time was 26.7 months, and 1-, 2-, and 3-year distant metastasis-free survival rates were 92.3%, 83.9%, and 65.3%, respectively. Gross tumor volume was the most significant prognostic factor for overall survival. No grade 4 or more toxicity was observed. Conclusions: Helical tomotherapy in patients with inoperable NSCLC resulted in high survival rates with an acceptable level of toxicity, suggesting it is an effective treatment option in patients with medically inoperable NSCLC.